Dihydrotachysterol

Summary

Dihydrotachysterol (CHEMBL2356023) is an approved small-molecule bone density conservation agent (ATC A11CC02).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A11CC02
• Chemistry: 398.7 Da · C28H46O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2356023
Name	Dihydrotachysterol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5311071
ChEBI	CHEBI:4591
ATC	A11CC02
Molecular formula	C28H46O
Molecular weight	398.7
InChIKey	ILYCWAKSDCYMBB-OPCMSESCSA-N

SMILES: C[C@H]\1CC[C@@H](C/C1=C\C=C\2/CCC[C@]3([C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C)O

IUPAC name: trans-(1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol

ChEBI definition: A hydroxy seco-steroid that is 9,10-secoergosta-5,7,22-triene substituted by a hydroxy group at position 3. A synthetic analogue of vitamin D that acts a bone density conservation agent.

Pharmacological roles (ChEBI): bone density conservation agent.

Also known as: A.t. 10, Dihidrotaquisterol, Dihydral, Dihydrotachysterol, Dihydrotachysterol 2, Dihydrotachysterol2, Dygratyl, Hytakerol, Tachyrol, Tachysterol dihydro derivative, SID29217905, SID50111742

Patent coverage: 1,775 distinct patent families (4,907 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Nuclear receptor ROR-gamma, Progesterone receptor, Menin/Histone-lysine N-methyltransferase MLL, Androgen receptor, Nuclear receptor subfamily 1 group I member 2.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 6 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR1I2	5.21	AC50	6200	nM	CHEMBL_ACT_25188227

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).